PTGX

Protagonist Therapeutics, Inc. - Common Stock (PTGX)

About Protagonist Therapeutics, Inc. - Common Stock (PTGX)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Details

Daily high

$143.30

Daily low

$134.39

Price at open

52 Week High

$160.81

52 Week Low

$76.70

Market cap

9.3B

Dividend yield

Volume

229

Avg. volume

689,706

P/E ratio

138.24

Protagonist Therapeutics, Inc. - Common Stock News